Wednesday's results are also a sigh of relief for Moderna after the company pushed back its experimental flu shot program in April.
Moderna compared the flu vaccine, dubbed mRNA-1010, to a currently approved seasonal flu vaccine from GlaxoSmithKline called Fluarix.
Moderna's flu shot also generated higher seroconversion rates, which refers to the development of specific antibodies against a virus.
Also on Wednesday, Moderna said it is ending a separate phase three trial on the first version of its flu vaccine.
"With today's positive phase 3 flu results, along with previous results in Covid and RSV, we are now three for three on advancing respiratory disease programs to positive phase 3 data."
Persons:
Moderna, Stephane Bancel
Organizations:
Moderna, U.S, GlaxoSmithKline, World Health Organization –, Food and Drug Administration, FDA, Pfizer, GSK
Locations:
Moderna, Covid